Premium
Drug Delivery: Synergistic Enhancement of Lung Cancer Therapy Through Nanocarrier‐Mediated Sequential Delivery of Superantigen and Tyrosin Kinase Inhibitor (Adv. Funct. Mater. 35/2014)
Author(s) -
Li Da,
Li Yongbin,
Xing Haibo,
Guo Junling,
Ping Yuan,
Tang Guping
Publication year - 2014
Publication title -
advanced functional materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.069
H-Index - 322
eISSN - 1616-3028
pISSN - 1616-301X
DOI - 10.1002/adfm.201470230
Subject(s) - nanocarriers , cancer research , drug delivery , superantigen , lung cancer , materials science , cetuximab , tyrosine kinase , drug , pharmacology , medicine , cancer , t cell , immunology , colorectal cancer , nanotechnology , immune system , oncology , receptor
Supramolecular cationic polymers, developed by Y. Ping, G. Tang, and co‐workers on page 5482, are designed for the sequential delivery of immunotherapeutic agents and molecular targeted drugs to fight lung cancer. This new therapeutic modality combines the advantages of superantigens to activate antitumor immunity and the specificity feature of tyrosine kinase inhibitors to selectively induce tumor cell apoptosis, and reveals a synergistic effect on tumor inhibition over mouse models with lung carcinoma xenografts. The supramolecular cationic polymers can potentially be used for treating a wide spectrum of cancers.